We are live on ! Find out more
CCM

Consonance Capital Management Portfolio holdings

AUM $7.28M
1-Year Est. Return 43.59%
This Fund
S&P 500
This Quarter Est. Return
+17.71%
1 Year Est. Return
-43.59%
3 Year Est. Return
+313.86%
5 Year Est. Return
+886.32%
10 Year Est. Return
–
AUM
$1.55B
AUM Growth
+$456M
Cap. Flow
+$316M
Cap. Flow %
20.36%
Top 10 Hldgs %
61.57%
Holding
33
New
7
Increased
11
Reduced
3
Closed
4

Top Buys

Rank Stock Value
1
PBYI icon
Puma Biotechnology
PBYI
+$121M
2
KPTI icon
Karyopharm Therapeutics
KPTI
+$78.6M
3
NVRO
NEVRO CORP.
NVRO
+$78.2M
4
EXEL icon
Exelixis
EXEL
+$66.4M
5
PCRX icon
Pacira BioSciences
PCRX
+$38.6M

Top Sells

Rank Stock Value
1
RDUS
Radius Health, Inc.
RDUS
+$104M
2
IOVA icon
Iovance Biotherapeutics
IOVA
+$54.2M
3
AMRN
Amarin Corp
AMRN
+$39.5M
4
DVAX
Dynavax Technologies
DVAX
+$32.9M
5
CORT icon
Corcept Therapeutics
CORT
+$9.74M

Sector Composition

Rank Sector Weight
1 Healthcare 99.36%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPPI
1
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
$146M 9.41%
6,963,756
+760,400
+12% +$14.1M
PBYI icon
2
Puma Biotechnology
PBYI
$402M
$124M 7.97%
+2,089,117
New +$121M
PCRX icon
3
Pacira BioSciences
PCRX
$1.06B
$120M 7.76%
3,753,834
+1,118,918
+42% +$38.6M
TVTX icon
4
Travere Therapeutics
TVTX
$5.33B
$105M 6.76%
3,843,371
+150,000
+4% +$3.99M
VNDA icon
5
Vanda Pharmaceuticals
VNDA
$312M
$87.8M 5.66%
4,609,043
+1,536,768
+50% +$25.7M
KPTI icon
6
Karyopharm Therapeutics
KPTI
$159M
$81M 5.22%
+317,805
New +$78.6M
NVRO
7
DELISTED
NEVRO CORP.
NVRO
$75.3M 4.86%
+943,070
New +$78.2M
URGN icon
8
UroGen Pharma
URGN
$2B
$74M 4.77%
1,487,491
+341,294
+30% +$19.9M
CORT icon
9
Corcept Therapeutics
CORT
$12.7B
$72.8M 4.69%
4,628,417
-560,000
-11% -$9.74M
EXEL icon
10
Exelixis
EXEL
$14.1B
$69.1M 4.45%
+3,209,200
New +$66.4M
UTHR icon
11
United Therapeutics
UTHR
$26.2B
$64.1M 4.14%
566,926
– –
NUVA
12
DELISTED
NuVasive, Inc.
NUVA
$57.3M 3.7%
1,099,523
– –
GWPH
13
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$50.8M 3.28%
364,300
+91,600
+34% +$13M
VSTM icon
14
Verastem
VSTM
$536M
$49.3M 3.18%
+597,222
New +$36.6M
PACB icon
15
Pacific Biosciences
PACB
$460M
$44.6M 2.88%
12,576,002
– –
STML
16
DELISTED
Stemline Therapeutics, Inc.
STML
$44.1M 2.84%
2,747,198
+140,600
+5% +$2.51M
LMNX
17
DELISTED
Luminex Corp
LMNX
$42.5M 2.74%
+1,440,126
New +$37M
QURE icon
18
uniQure
QURE
$2.93B
$39.5M 2.55%
1,045,065
– –
VCEL icon
19
Vericel Corp
VCEL
$2.43B
$35M 2.26%
3,608,092
+503,500
+16% +$6.27M
SVRA icon
20
Savara
SVRA
$1.14B
$30.7M 1.98%
2,711,190
– –
OXFD
21
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$30.2M 1.94%
2,339,184
– –
ADMA icon
22
ADMA Biologics
ADMA
$2.01B
$19.2M 1.24%
4,249,234
+920,000
+28% +$4.59M
CPRX
23
DELISTED
Catalyst Pharmaceutical
CPRX
$18.9M 1.22%
6,044,719
+1,050,000
+21% +$3.19M
AMRN
24
Amarin Corp
AMRN
$298M
$15.4M 0.99%
248,433
-638,064
-72% -$39.5M
CARM
25
DELISTED
Carisma Therapeutics
CARM
$14.7M 0.95%
+376,165
New +$16.6M
1
2

Similar funds

GPC
Garrison Point Capital Walnut Creek, California $6.82M AUM 21.38% 1-Year Est. Return
BPM
Bronson Point Management Fairfield, Connecticut $8.26M AUM 46.43% 1-Year Est. Return
TVPI
True Venture Partners IV Palo Alto, California $8.41M AUM 78.89% 1-Year Est. Return
DCI
Data Collective II Palo Alto, California $8.44M AUM 11.7% 1-Year Est. Return
TPMI
Tilden Park Management I New York $5.38M AUM 28.49% 1-Year Est. Return
TP
Truvvo Partners New York $5.22M AUM 13.74% 1-Year Est. Return
SCG
Siris Capital Group New York $9.42M AUM 42.79% 1-Year Est. Return
CVGI
Craft Ventures GP I San Francisco, California $9.51M AUM 95.77% 1-Year Est. Return

Consonance Capital Management's Q2 2018 Portfolio in Review

As of Q2 2018, Consonance Capital Management held 33 positions worth $1.55B, up 42% from $1.09B the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Consonance Capital Management deployed $316M of net new capital in Q2 2018, opening 7 new positions and adding to 11 existing holdings. Its largest new stake was Puma Biotechnology: 2,089,117 shares worth $124M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 90% a quarter earlier.

On the sell side, the largest reduction was Amarin Corp, an estimated $39.5M trimmed.

  • Consonance Capital Management's largest Q2 2018 buy was Puma Biotechnology: 2,089,117 shares worth $124M.
  • Consonance Capital Management added most to Pacira BioSciences in Q2 2018, an estimated $38.6M increase.
  • Consonance Capital Management's biggest Q2 2018 reduction was Amarin Corp, cutting an estimated $39.5M.
  • Consonance Capital Management fully exited Radius Health, Inc. in Q2 2018, selling an estimated $104M.
  • Consonance Capital Management's ten largest holdings make up 62% of its $1.55B portfolio in Q2 2018.
  • Consonance Capital Management opened 7 new positions and closed 4 in Q2 2018.
  • Consonance Capital Management's portfolio value rose 42% quarter-over-quarter to $1.55B.

Based on Consonance Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.